Suramin in hormone-refractory metastatic prostate cancer: a drug with limited efficacy.

Nonparametric Estimation from Incomplete Observations

1992 • 45,923 citations

Regression Models and Life-Tables

1992 • 27,454 citations

The Statistical Analysis of Failure Time Data.

1981 • 10,224 citations

Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response.

1989 • 417 citations

Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer.

1993 • 417 citations

Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer.

1993 • 400 citations

Suramin Protection of T Cells in Vitro Against Infectivity and Cytopathic Effect of HTLV-III

1984 • 396 citations

Suramin: an anticancer drug with a unique mechanism of action.

1989 • 370 citations

A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma.

1985 • 267 citations

Suramin binds to platelet‐derived growth factor and inhibits its biological activity

1985 • 257 citations

Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer.

1992 • 256 citations

Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer.

1992 • 237 citations

Suramin Blockade of Insulinlike Growth Factor I-Stimulated Proliferation of Human Osteosarcoma Cells

1990 • 149 citations

Transformation of NIH 3T3 cells with basic fibroblast growth factor or the hst/K-fgf oncogene causes downregulation of the fibroblast growth factor receptor: reversal of morphological transformation and restoration of receptor number by suramin.

1989 • 143 citations

Suramin, an Active Drug for Prostate Cancer: Interim Observations in a Phase I Trial

1993 • 133 citations

Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer.

1994 • 118 citations

Inhibition of Prostate Cancer Growth by Estramustineand Etoposide: Evidence For Interaction at the Nuclear Matrix

1993 • 103 citations

Identification of Epidermal Growth Factor-Like Activity in Human Male Reproductive Tissues and Fluids*

1984 • 95 citations

Experimental animal model for mucopolysaccharidosis: suramin-induced glycosaminoglycan and sphingolipid accumulation in the rat.

1980 • 79 citations

Inhibition of Prostatic Tumor Cell Proliferation by Suramin: Alterations in TGF Alpha-Mediated Autocrine Growth Regulation and Cell Cycle Distribution

1991 • 60 citations

Use of adaptive control with feedback to individualize suramin dosing.

1992 • 59 citations

Phase II trial of suramin in patients with advanced renal cell carcinoma: treatment results, pharmacokinetics, and tumor growth factor expression.

1992 • 53 citations

Synergistic Activity of Suramin With Tumor Necrosis Factor and Doxorubicin on Human Prostate Cancer Cell Lines

1990 • 48 citations

Inhibition of Breast Cancer Growth by Suramin

1992 • 44 citations

Effects of Suramin on In Vitro Growth of Fresh Human Tumors

1992 • 44 citations

A Critical Assessment of the Role of Chemotherapy for Endocrine-Resistant Prostatic Carcinoma

1987 • 36 citations

Suramin-Induced Skin Reactions

1992 • 35 citations

Implementation and evaluation of control strategies for individualizing dosage regimens, with application to the aminoglycoside antibiotics

1986 • 26 citations

Bioanalysis of suramin in human plasma by ion-pair high-performance liquid chromatography

1990 • 13 citations

Postoperative complications in patients receiving suramin therapy.

1994 • 10 citations